Nanjing Well Pharmaceutical Group Co (SHSE:603351) Total Liabilities : ¥661 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Nanjing Well Pharmaceutical Group Co Total Liabilities?

Nanjing Well Pharmaceutical Group Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥661 Mil.

Nanjing Well Pharmaceutical Group Co's quarterly Total Liabilities declined from Sep. 2023 (¥732.74 Mil) to Dec. 2023 (¥686.22 Mil) and declined from Dec. 2023 (¥686.22 Mil) to Mar. 2024 (¥660.59 Mil).

Nanjing Well Pharmaceutical Group Co's annual Total Liabilities increased from Dec. 2021 (¥456.01 Mil) to Dec. 2022 (¥655.76 Mil) and increased from Dec. 2022 (¥655.76 Mil) to Dec. 2023 (¥686.22 Mil).

Nanjing Well Pharmaceutical Group Co Total Liabilities Historical Data

The historical data trend for Nanjing Well Pharmaceutical Group Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Well Pharmaceutical Group Co Total Liabilities Chart

Nanjing Well Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

217.06

336.75

456.01

655.76

686.22

Nanjing Well Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															701.85	706.93	732.74	686.22	660.59

Nanjing Well Pharmaceutical Group Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nanjing Well Pharmaceutical Group Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	557.748	+	(104.064	+	24.41
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	686

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2278.903	-	1592.681
	=	686

Nanjing Well Pharmaceutical Group Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	533.597	+	(102.428	+	24.566
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	661

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	2288.162	-	1627.57
	=	661

Nanjing Well Pharmaceutical Group Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Nanjing Well Pharmaceutical Group Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Well Pharmaceutical Group Co (SHSE:603351) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Well Pharmaceutical Group Co Ltd (SHSE:603351) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

No. 99, Changfeng Hexi Road, Nanjing Chemical Industry Park, Jiangsu Province, Nanjing, CHN, 210000

Website

http://www.well-js.com

Nanjing Well Pharmaceutical Co Ltd is engaged in research and development, production and sales of pharmaceutical auxiliary materials and synthetic lubricating base oil and other products. The company uses a variety of pharmaceutical dosage forms such as injection, oral administration and external use to guarantee the molding, effectiveness, stability and safety of pharmaceutical dosage forms.

Executives

Wang Fu Qiu	Directors, senior managers
Zou Jian Guo	senior management
Wu Rong Wen	Supervisors

Nanjing Well Pharmaceutical Group Co (SHSE:603351) Headlines

No Headlines